Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus delayed reduced-dose prolonged-release tacrolimus after kidney transplantation in elderly patients
2008-003189-25Phase 4Terminated
- Sponsor
- AIREN
- Start
- Jan 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus, basiliximab and mycophenolic acid in kidney transplant (2 arms), sponsored by AIREN. Primary endpoint: Renal function at 6 months after transplantation. Started Jan 2011; status: terminated.
02
Drugs
tacrolimusbasiliximabmycophenolic acid
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2008-003189-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003189-25.